Drugs / ZFN Modified CD4+ T Cells
ZFN Modified CD4+ T Cells
also known as
ZFN-modified autologous CD4 T cells
Cell therapy targets CCR5 via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00842634 | Jan 2009 → Jan 2013 | HIV infectious disease | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZFN Modified CD4+ T Cells | “A single infusion of 5-10 billion ZFN Modified CD4+ T Cells” NCT00842634 ↗ |
| Known as | ZFN-modified autologous CD4 T cells | “We enrolled 12 patients in an open-label, nonrandomized, uncontrolled study of a single dose of ZFN-modified autologous CD4 T cells.” PMID 24597865 ↗ Mar 2014 |
| Action | Inhibit | “ZFNs knock out the CCR5 protein” NCT00842634 ↗ |
| Modality | Cell therapy | “ZFN-modified autologous CD4 T cells” PMID 24597865 ↗ Mar 2014 |
| Target | CCR5 | “the CCR5 gene was rendered permanently dysfunctional” PMID 24597865 ↗ Mar 2014 |